Home
About SinovacProductsPipelineInvestorsContact Us
 
 
  SITEMAP 中文版
         
 
 
SINOVAC OVERVIEW
Sinovac Biotech Ltd. (also known in China as Beijing Kexing Bioproducts) specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”. Sinovac is one of the leading emerging biotechnology companies in China.

Working closely with Chinese public health officials, Sinovac focuses on manufacturing and marketing human-use vaccines and related products, and currently markets its vaccine for Hepatitis A. Sinovac is the first and currently the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS.
 
     

GET LATEST NEWS
Enter your email below to receive up-to-date info:
Your name
Email
Subscribe

 
LATEST NEWS More Info
  • Sinovac Biotech Holds Annual General Meeting »
  • Sinovac Receives SFDA's Approval for Pandemic Influenza H5N1 Vaccine »
  • Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results »
  • Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results »
  • Sinovac Announces Adjournment of Annual General Meeting »
  •  
     
     
    WEB RESOURCES   GO
    INFO RESOURCES  
    Copyright © 2001-2008 Sinovac Biotech Ltd. All rights reserved.